Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Watch
Expert ConversationsShows & PodcastNews & Analysis
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Alexander N. Shoushtari, MD

Advertisement

Articles by Alexander N. Shoushtari, MD

First-in-Human Trial for Tebentafusp In Advanced Melanoma Shows Promising Safety Profile

ByAlexander N. Shoushtari, MD
November 26th 2019

The first-in-human trial for tebentafusp findings are in, and they show promise for managing a patients side effects to it.

Advertisement

Latest Updated Articles

  • First-in-Human Trial for Tebentafusp In Advanced Melanoma Shows Promising Safety Profile
    First-in-Human Trial for Tebentafusp In Advanced Melanoma Shows Promising Safety Profile

    November 26th 2019



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Oral Giredestrant Shifts Care Home: How Nurses Can Support Adherence

2

Nurses Are Key to Keeping Complex Cancer Care Close to Home

3

Chris Draft: Nurses Translate a Lung Cancer Diagnosis Into a Game Plan

4

Giredestrant Approval: What Nurses Need to Know and What Comes Next

5

FDA Grants Accelerated Approval to Neladalkib in Pretreated ALK+ NSCLC

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us